Pharmacology Of Potential Anti-Tumour Agents: Iron Chelators Of The BpT Class
Funder
National Health and Medical Research Council
Funding Amount
$585,455.00
Summary
Pharmacology of Potential Anti-Tumour Agents: Iron Chelators of the BpT Class Cancer cells have a high iron requirement for DNA synthesis and many clinical trials showed Fe chelators are effective anti-cancer drugs. Their potential to act as anti-tumour agents has been confirmed by the entrance of Triapine into widespread NCI clinical trials. In this NHMRC Renewal, we will perform pharmacological and preclinical studies to promote the development of BpT chelators as novel anti-tumour agents.
Industrial Transformation Research Hubs - Grant ID: IH220100017
Funder
Australian Research Council
Funding Amount
$4,808,669.00
Summary
ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals. Radiopharmaceuticals are emerging as next generation medical technologies for addressing complex health challenges, and their manufacture offers significant economic benefit to Australia. The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The progra ....ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals. Radiopharmaceuticals are emerging as next generation medical technologies for addressing complex health challenges, and their manufacture offers significant economic benefit to Australia. The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The program addresses industry-led challenges for translation of biologics as molecular radiopharmaceuticals, building capacity in biomanufacturing, radiobiology and radiochemistry. The program establishes a dedicated manufacturing pipeline, future-proofing production and securing supply chain of next generation medical technologies.Read moreRead less
Industrial Transformation Training Centres - Grant ID: IC170100016
Funder
Australian Research Council
Funding Amount
$3,123,492.00
Summary
ARC Training Centre for Personalised Therapeutics Technologies. The ARC Training Centre for Personalised Therapeutics Technologies aims to create and develop the skills and technology to benefit from the transformative impacts that cell/organ-on-a-chip technology will have on the medtech/pharma industries. By combining microfluidics-based/real-time technologies with personalised medicine the Training Centre will provide industry growth opportunities through improved screening of potential therap ....ARC Training Centre for Personalised Therapeutics Technologies. The ARC Training Centre for Personalised Therapeutics Technologies aims to create and develop the skills and technology to benefit from the transformative impacts that cell/organ-on-a-chip technology will have on the medtech/pharma industries. By combining microfluidics-based/real-time technologies with personalised medicine the Training Centre will provide industry growth opportunities through improved screening of potential therapeutics. The use of an individual patient’s cellular and molecular research findings will ultimately enable personalised diagnostic and therapeutic decisions.Read moreRead less
Fundamentals and applications of continuous-flow microprocessing systems based on supercritical fluids and gas expanded liquids. Microchemical systems have considerable potential in the area of chemical discovery and development. Practical application of these systems requires fundamental understanding and strategies for conversion to appropriate scale. The aim of this project is to overcome such challenges in the development of microstructured continuous-flow technology.
Unleashing the Hidden Chemical Diversity in Australian Fungi. This project aims to exploit an exclusive genomic resource consisting of >150 unique Australian filamentous fungi that has been built in a university-industry collaboration for genomic-guided biodiscovery. The genome sequence of these fungi revealed extensive hidden genetic instructions for production of novel biologically active molecules. The project will apply cutting-edge synthetic biology and chemical tools to tap into the hidden ....Unleashing the Hidden Chemical Diversity in Australian Fungi. This project aims to exploit an exclusive genomic resource consisting of >150 unique Australian filamentous fungi that has been built in a university-industry collaboration for genomic-guided biodiscovery. The genome sequence of these fungi revealed extensive hidden genetic instructions for production of novel biologically active molecules. The project will apply cutting-edge synthetic biology and chemical tools to tap into the hidden genomic potential of these Australian fungi. Expected outcomes of this project include new fine chemicals and lead molecules with desirable bioactivies. This will provide significant benefits to Australia's economy through the discovery of new pharmaceuticals, veterinary products and agrichemicals.Read moreRead less
Industrial Transformation Training Centres - Grant ID: IC170100035
Funder
Australian Research Council
Funding Amount
$4,743,710.00
Summary
ARC Training Centre for Innovation in Biomedical Imaging Technology. The ARC Training Centre for Innovation in Biomedical Imaging Technology expects to train 20 industry-ready innovation scientists who will undertake industry-driven research in the development and application of novel diagnostics, therapeutics and theranostics. They will inform changes in regulatory policy that support industry growth. The Centre will build multidisciplinary links between researchers and within industry to devel ....ARC Training Centre for Innovation in Biomedical Imaging Technology. The ARC Training Centre for Innovation in Biomedical Imaging Technology expects to train 20 industry-ready innovation scientists who will undertake industry-driven research in the development and application of novel diagnostics, therapeutics and theranostics. They will inform changes in regulatory policy that support industry growth. The Centre will build multidisciplinary links between researchers and within industry to develop ‘smart’ probes and ‘smart’ scanning, harnessing the digital revolution for better, cost effective diagnostic imaging and improved health outcomes.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE130100164
Funder
Australian Research Council
Funding Amount
$310,000.00
Summary
A facility for ex-vivo molecular imaging. The facility will allow a consortium of Australian researchers to create an integrated facility for imaging biological receptors in tissue, bringing together laboratory, radiochemistry and imaging expertise. Digital data at each site will be able to be viewed and analysed remotely.
Mid-Career Industry Fellowships - Grant ID: IM230100154
Funder
Australian Research Council
Funding Amount
$1,049,904.00
Summary
Fungi Power: Designer Fungal Cell Factories for Advanced Biomanufacturing. This project aims to build an advanced biomanufacturing platform based on filamentous fungi in collaboration with industry. Using synthetic biology, the project expects to engineer superior fungal host strains customisable to the needs of the industry and to address their technological gaps. The expected outcomes include the development of cost-efficient and sustainable fungal-based bioprocesses for the companies to produ ....Fungi Power: Designer Fungal Cell Factories for Advanced Biomanufacturing. This project aims to build an advanced biomanufacturing platform based on filamentous fungi in collaboration with industry. Using synthetic biology, the project expects to engineer superior fungal host strains customisable to the needs of the industry and to address their technological gaps. The expected outcomes include the development of cost-efficient and sustainable fungal-based bioprocesses for the companies to produce products, such as fine chemicals, pharmaceutical actives and food ingredients. The project would provide significant benefits by enabling existing and emerging companies' commercial successes and competitiveness in global markets, creating new jobs and resulting in the growth of the bio-economy in Australia.Read moreRead less
ARC Centre of Excellence in Synthetic Biology. The ARC Centre of Excellence in Synthetic Biology (CoESB) will provide the technical innovation critical for Australia to develop a vibrant bioeconomy building on the nation’s strengths in agriculture. For thousands of years we have used microbes to create bread, wine, cheese. Now, our Centre will pioneer new approaches to the design of synthetic microbes, enabling the development of custom-designed microbial communities, synthetic organelles and ne ....ARC Centre of Excellence in Synthetic Biology. The ARC Centre of Excellence in Synthetic Biology (CoESB) will provide the technical innovation critical for Australia to develop a vibrant bioeconomy building on the nation’s strengths in agriculture. For thousands of years we have used microbes to create bread, wine, cheese. Now, our Centre will pioneer new approaches to the design of synthetic microbes, enabling the development of custom-designed microbial communities, synthetic organelles and new to nature biological pathways and enzymes. CoESB will combine engineering with molecular biology to design and construct novel biological systems that can convert biomass from agriculture or waste streams to biofuel, bioplastics and other high-value chemicals.Read moreRead less
A novel drug class for the effective treatment of Giardia infections. Companion animals play a pivotal role in the lifestyle of the average Australian family. The 9 million cats and dogs, residing in >65% of our households, have provided significant health and well-being benefits to owners, especially during COVID. Ensuring pet health is a primary obligation of pet ownership. Giardia infections (Giardia duodenalis, with 94% of infections in dogs identified as Assemblage A) is the most prevalent ....A novel drug class for the effective treatment of Giardia infections. Companion animals play a pivotal role in the lifestyle of the average Australian family. The 9 million cats and dogs, residing in >65% of our households, have provided significant health and well-being benefits to owners, especially during COVID. Ensuring pet health is a primary obligation of pet ownership. Giardia infections (Giardia duodenalis, with 94% of infections in dogs identified as Assemblage A) is the most prevalent enteric parasite identified globally in dogs. Infection rates can be as high as 75% in puppies. Current treatments are failing due to poor efficacy, resistance and poor adherence to treatment schedules. We have identified a novel, extremely rapid acting series of compounds capable of single shot eradication of Giardia.Read moreRead less